Clinical trials: Non-Insulin Dependent
Cardiovascular Diseases, Heart Diseases
Prospective Study of Diabetes-related Vascular Disease in Oklahoma Indians
To study the relationship between diabetes and various macro- and microvascular complications in Oklahoma Indians.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Diabetes Mellitus, Non-insulin Dependent, Diabetes Mellitus
- Trial name
- NCT00005193
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Type 2 Diabetes Mellitus, Postprandial Hyperglycemia
Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)
The postprandial phase in diabetic patients is characterized by a rapid increase in blood glucose levels, increase in platelet aggregation, LDL oxidation and over production of thrombin.
- Trial name
- NCT00771693
- Testing
- Insulin aspart (Novorapid®)
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Karolinska Institutet
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Glucose Intolerance, Hyperinsulinemia
Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes
This study is for women who have already decided to undergo liposuction at Georgetown University Medical Center in Washington, D.C.
- Conditions
- Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
- Trial name
- NCT00005760
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Atherosclerosis, Cardiovascular Diseases
Multi-Ethnic Study of Atherosclerosis (MESA)
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease
- Trial name
- NCT00005487
- Volunteers
- 6,418 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Heart Diseases
Weight Loss Maintenance (WLM)
To determine the effectiveness of continuous patient contact on weight loss maintenance.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Obesity, Diabetes Mellitus, Non-insulin Dependent
- Trial name
- WLM (NCT00054925)
- Testing
- Personal contact (PC), Interactive technology (IT)
- Volunteers
- 1,685 people
- Sponsor
- Duke University
Diabetes Mellitus, Type 2
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
- Trial name
- NCT00886821
- Testing
- CVX-096
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM
Blacks or African Americans have greater risk of and are more likely to die from type 2 diabetes (T2DM). Major barriers to effective diabetes care for Blacks include poor diabetes knowledge, self-management skills, empowerment…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent
- Trial name
- DM-TBSI (NCT00929838)
- Testing
- Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- State University of New York at Buffalo
Diabetes Mellitus, Non-Insulin-Dependent
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent.
- Trial name
- OPTIMISE (NCT01694758)
- Where
- 20 sites in Bulgaria, Romania
- Volunteers
- 733 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Diabetes Mellitus, Non-insulin Dependent
Dyslipidemia and Risk of Cardiovascular Disease in Diabetic Men and Women
To determine the role of dyslipidemia, markers of endothelial dysfunction genetic susceptibility, and dietary fat intake on the development of cardiovascular disease (CVD) complications in Type II diabetes mellitus.
- Conditions
- Cardiovascular Diseases, Diabetes Mellitus, Non-insulin Dependent, Heart Diseases, Atherosclerosis
- Trial name
- NCT00037258
- Sponsor
- Brigham and Women's Hospital
Non-Small Cell Lung Cancer
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with…
- Trial name
- LuCa-MERIT-1 (NCT05142189)
- Testing
- BNT116, Cemiplimab, Docetaxel
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 320 people
- Sponsor
- BioNTech SE
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Diabetes Mellitus, Non-Insulin-Dependent, Heart Failure
Saxagliptin and Cardiac Structure and Function
Diabetes is associated with a substantially increased risk of heart failure, which is associated with substantial morbidity and mortality.
- Trial name
- SCARF (NCT02481479)
- Testing
- Saxagliptin
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Unity Health Toronto
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
- Trial name
- NCT00291356
- Testing
- GSK189075 oral tablets, GW869682 oral tablets
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Non-Insulin-Dependent
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas.
- Trial name
- NCT00071422
- Testing
- INGAP-Peptide
- Where
- 17 sites in United States
- Volunteers
- 126 people
- Sponsor
- Exsulin Corporation
Cardiovascular Diseases, Diabetes Mellitus, Non-insulin Dependent
Epidemiology of Cardiovascular Disease in Diabetes
To locate and identify genes contributing to the genetic component of subclinical cardiovascular disease (CVD) in Type 2 diabetes and to evaluate the impact of lifestyle and environment on the expression of these genetic…
- Conditions
- Cardiovascular Diseases, Diabetes Mellitus, Non-insulin Dependent, Heart Diseases, Atherosclerosis
- Trial name
- NCT00037297
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Coronary Heart Disease, Dyslipidemia
Cardiovascular Risk Factor Management in HIV Infection
There is growing evidence that antiretroviral therapy (ART) increases the risk of coronary heart disease (CHD) through metabolic side effects, such as dyslipidemia, insulin resistance, and type II diabetes.
- Conditions
- Coronary Heart Disease, Dyslipidemia, Diabetes Mellitus, Non-Insulin-Dependent, HIV Infection
- Trial name
- NCT00264394
- Testing
- Updated CHD risk profiles, Guidelines
- Where
- 7 sites in Switzerland
- Volunteers
- 4,097 people
- Sponsor
- University Hospital, Basel, Switzerland
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT03302234
- Testing
- Pembrolizumab, Ipilimumab
- Where
- 187 sites in United States, Argentina and 22 more
- Volunteers
- 568 people
- Sponsor
- Merck Sharp & Dohme LLC